---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-004159"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2025-01-16T23:59:59+00:00"
generated_at: "2026-05-28T00:06:20.136794+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics raises ~$20.5M via warrant inductions; ONS-5010 meets noninferiority at week 12 in AMD trial

## Summary
- Exercised existing warrants for ~$17.8M gross (including $8.7M from GMS Ventures) and ~$2.7M from Syntone.
- Issued inducement warrants for 14.1M shares (Tranche A immediate, Tranche B subject to shareholder approval) at $2.26 exercise price.
- In NORSE EIGHT, ONS-5010 showed +5.5 letters BCVA improvement at week 12, meeting noninferiority (p=0.0043) vs ranibizumab.
- Plans to resubmit BLA for ONS-5010 in Q1 2025 based on complete 12-week safety and efficacy data.
- No retinal vasculitis reported; safety profile comparable to ranibizumab across all study timepoints.

## SEC filing metadata
- accession: 0001104659-25-004159
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2025-01-16T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 3.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465925004159/0001104659-25-004159-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465925004159/tm253522d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-004159
- JSON: https://secwatch.observer/filing/0001104659-25-004159.json
- Plain text: https://secwatch.observer/filing/0001104659-25-004159.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.